Summary A major complication of in vivo monoclonal antibody therapy in patients with cancer is the host's immune response to the administered xenogeneic immunoglobulin. We have performed parallel clinical and experimental studies to investigate the possibility that deaggregation of the therapeutic monoclonal antibody might render it non-immunogenic, or even tolerogenic, as has been suggested in several animal studies. Deaggregation of xenogeneic immunoglobulin has been shown by others to induce non-responsiveness in some ('susceptible') but not in other ('resistant') strains of mice. We have used an improved deaggregation method of size exclusion chromatography connected to FPLC and have developed a sensitive ELISA detection system to determine whether highly purified human immunoglobulin G (hIgG) monomers could be tolerogenic even to 'resistant' mice. However, our data show that all preparations of hIgG are immunogenic to 'resistant' mice, and that although deaggregation does significantly reduce the anti-hIgG response of 'susceptible' strains, tolerance is not induced. Concommitant administration of cyclosporin A and deaggregated hIgG had a additive effect in reducing the murine anti-hIgG secondary response. In clincial studies of patients with ovarian cancer who received in vivo immunotherapy with either iodine-131 (not aggregated) or yttrium-90 (aggregated) HMFGI mouse monoclonal antibody, no significant difference was found between the immune responses to aggregated and non-aggregated murine immunoglobulin G. Our data suggest that deaggregation alone is unlikely to be useful in controlling the human anti-murine immunoglobulin G response in our outbred patient population, although in combination with an immunosuppressant it may be more effective.
Over the past decade monoclonal antibodies have made an increasingly important contribution to the in vivo diagnosis and treatment of cancer (Chatal et al., 1984; Carrasquillo et al., 1986; Epenetos et al., 1987) . However, despite promising results, their clinical potential has been limited, in part, by their immunogenicity. Most monoclonal antibodies are of mouse or rat origin and are therefore recognised as foreign by the human recipient (Schroff et al., 1985; Courtenay-Luck et al., 1986) . The resultant human anti-mouse immunoglobulin (Ig) antibodies create two problems. Firstly, they form immune complexes with the administered monoclonal antibody and are rapidly cleared from the body, thus reducing the ability of the antibody to reach its tumour target. Secondly, these complexes may lead to a type III hypersensitivity response (serum sickness). Repeated injections of therapeutic antibody are therefore not usually possible.
The aim of the present work was to study ways in which the administered monoclonal antibody could be made less immunogenic to the recipient. Experiments were performed in animals and, where possible, parallel data were obtained from the clinical situation. Our studies were based upon early reports that aggregation increases immunogenicity and that deaggregated immunoglobulin may not only be less immunogenic but may actually be tolerogenic (Dresser, 1962) . This tolerogenic effect was genetically controlled and dependent upon the method of deaggregation used (Lukic & Leskowitz, 1974; Golub & Weigle, 1969) . We have analysed the effects of 'antigen' deaggregation in three different strains of mice given polyclonal human IgG, and have in addition analysed the simultaneous effect of a well established immunosuppressive drug, cyclosporin A. Finally, in parallel clinical studies, the anti-mouse Ig response of patients with ovarian cancer, who had received non-aggregated and partially aggregated radiolabelled murine monoclonal antibody for therapeutic purposes, was monitored.
Material and methods

Mice
Female BALB/c, CBA and C57BL/6 mice, 8 -10 weeks old, were purchased from Olac Ltd, UK.
Human immunoglobulin G Polyclonal human immunoglobulin G (hIgG) (Sigma, UK.) was used as an immunogen for the mice. Each mouse received 70 or 100.tg of hIgG intraperitoneally.
Deaggregation of human IgG
The hIgG was purchased in lyophilised form. After reconstitution in phosphate buffered saline pH 7.4 (PBS), it was found to contain 20-25% aggregates. These aggregates were pelleted by centrifugation at 150,000g for 150 min (L8-70M, Beckman Instruments, Palo Alto, USA) and the 'deaggregated' contents of the top one-third of the centrifuge tube was then removed for use as an immunogen. The presence or absence of high molecular weight immunoglobulin aggregates was checked by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), silver stained, and by fast protein liquid chromatography (FPLC) analysis (Pharmacia, Sweden). In further experiments, monomeric hIgG was isolated by Superose 12 and 6 (Pharmacia, Sweden) size exclusion chromatography columns connected on to an FPLC (Figure la, b) . The monomeric fraction was used immediately after determination of concentration, in order to avoid reaggregation. SDS-PAGE analysis showed that after deaggregation by ultracentrifugation, a faint band at 300 kDa was visible; no such band was seen in the fraction purified by gel filtration.
Aggregation of human IgG Human IgG was heated for 2 h at 59°C and then left overnight on ice (Weigle, 1973 (Taylor-Papadimitriou et al., 1981) . HMFG1 was radiolabelled with either iodine-131 (Amersham International, UK) using the N-bromo-succinamide (Sigma) method (Reay, 1982) , or with yttrium-90 (AERE, Harwell, UK).
Before yttrium-90 labelling, the antibody was conjugated to diethylenetriamine penta-acetic acid (DTPA) (Sigma) by the cyclic anhydrate method (Hnatowitch et al., 1983 ). Yttrium-90 was then coupled to the antibody using a method based on that established for indium-ill (Hnatowitch et al., 1983; Paik et al., 1985) .
Assessment of aggregation of therapeutic monoclonal antibody preparations FPLC analysis and autoradiography of the HMFG1 before and 24 h after (serum sample) administration to the patients revealed that it was monomeric and that it remained monomeric after labelling with iodine-131 ( Figure 2a ). In contrast, yttrium-90-labelled HMFG1 was found to be partially aggregated (up to 40%) due to antibody cross-linkage via the bifunctional DTPA reagent ( Figure 2b ). Measurement of the anti-immunoglobulin response All blood samples were left to clot overnight at 4°C. They were then centrifuged and the supernatant serum removed, aliquoted and stored at -20°C. An enzyme-linked immunsorbent assay (ELISA) was used to measure the anti-Ig response. This has been described in detail elsewhere (Courtenay-Luck et al., 1986 reduce the mouse anti-hIgG response (Figure 5c Immune response ofpatients with cancer to therapeutic mouse IgG monoclonal antibody: effect of deaggregation Twenty-two patients with ovarian cancer were given approximately 15 mg monoclonal antibody HMFG1 intraperitoneally, for therapeutic purposes. Eleven received antibody labelled with iodine-131 (80-150mCi), while the other 11 received antibody labelled with yttrium-90 (5-20mCi). All patients were receiving monoclonal antibody treatment for the first time. Each patient's anti-mouse IgG response was measured before and 14 days after therapy. The iodine-131 labelled monoclonal antibody was monomeric (Figure 2a ), but the yttrium-90 labelled antibody contained up to 40% aggregates (Figure 2b ), due to the DTPA coupling procedure. No significant difference was observed between the antimouse IgG response of these two groups ( Figure 6 ).
Discussion
One of the major problems that has to be overcome before monoclonal antibody therapy for cancer can reach its full potential is the immunogenicity of the administered xenogeneic immunoglobulin. Since 1962 when Dresser first reported that he could induce tolerance to bovine gammaglobulin many investigators have supported the view that deaggregated IgG is tolerogenic in some strains of mice ('susceptible') but not in others ('resistant') (Golub & Weigle, 1969; Lukic et al., 1975a, b; Pepys & Taussig, 1974) The work presented in this paper was designed to investigate the possibility that deaggregation of the monoclonal antibodies used for in vivo therapy might render them tolerogenic to the recipient. We used two approaches. Firstly, we used a genetically 'inverted' experimental model in which we studied the immune response of mice to various preparations of human IgG to determine whether more stringent deaggregation could render IgG tolerogenic even to a 'resistant' animal. Secondly, we studied the immune responses of a series of patients with cancer to therapeutic mouse monoclonal antibody that was coupled with either iodine-131 (no aggregates) or yttrium-90 (contains aggregates). The degree of deaggregation appears to be crucial in obtaining pure tolerogenic Ig monomers. In previous studies, careful deaggregation using Na2SO4 fractionation or biological filtration (Golub & Weigle, 1969; Lukic et al., 1975b) was found to be more effective than ultracentrifugation (Dresser, 1962; Pepys & Taussig, 1974; Lukic et al., 1975b; Das & Leskowitz, 1970; Benjamin et al., 1986) for producing tolerogenic Ig. For this study we chose to deaggregate our IgG using FPLC gel filtration since this provides a rapid and highly efficient (>90% monomeric fraction recovered) method of deaggregation. A second important consideration is the method by which the anti-Ig response is detected. The main system used by previous investigators was the rate of biological clearance of iodine-125-labelled gammaglobulin (Golub & Weigle, 1969; Pepys & Taussig, 1974; Lukic et al., 1975b) . For the experiments presented here we have developed a highly sensitive ELISA to quantitate the anti-xenogeneic Ig response.
The induction of tolerance in mice to deaggregated IgG appears to be under genetic control. Thus, strains such as C57BL/6, A/J, DBA/2, CBA and C3H/HE mice have been shown to be 'susceptible' to the induction of unresponsiveness (Golub & Weigle, 1969; Lukic et al., 1975b; Fujiwara & Cinader, 1974; Staples et al., 1970) , whereas BALB/c, SJL, NZB and DDD mice are particularly 'resistant' (Golub & Weigle, 1969; Lukic et al., 1975a; Staples et al., 1970; Hosono et al., 1977; Playfair, 1971; Hosono & Fujiwara, 1979a, b 'responder' and 'non-responder' strains of mice, although the level of reduction was less and more variable in the 'responder' BALB/c strain (ranging from 65% reduction, Figure   3b to no effect, Figure 5a , b). The data therefore indicate that deaggregation leads to a reduction in immunogenicity, but we have no evidence for the induction of tolerance. Cyclosporin A reduces the primary and secondary B-cell immune responses, to both immunoglobulin preparations, presumably via its well known inhibitory action of T-cell activation and lymphokine secretion (Bickel et al., 1987; Krusemeier & Snow, 1988; Borel et al., 1977) . Additional experiments showed that the secondary immune response to deaggregated hIgG, in combination with CSA, resulted in a depression of the immune response, that was greater than that achieved with either factor alone. Similar co-operative effects between CSA and deaggregation have recently been described in rabbits given murine monoclonal antibody (Ledermann et al., 1988) .
Parallel studies on the effects of Ig aggregation were car-ried out in 22 patients with cancer, who were receiving immunotherapy, where we could compare the immune response generated to non-aggregated (iodine-131 labelled) and aggregated (yttrium-90 labelled) mouse monoclonal antibody. However, in this situation both preparations were found to be equally immunogenic (Figure 6 ), despite the fact that the non-aggregated iodine-131 preparation was composed of pure monomers, as shown by FPLC (Figure 2 ) or SDS-PAGE analysis. These findings can probably be attributed to the fact that genetically controlled immune response differences would be difficult to see in the outbred human population. Alternatively, it is possible that we are underestimating the immune response to aggregated murine Ig since yttrium-90-labelled monoclonal antibodies result in higher bone marrow toxicity (and hence immunosuppression) than those labelled with iodine-131 (unpublished observations). A further contributory factor in our inability to induce tolerance to monomeric murine Ig in patients may be the fact that the therapeutic antibody has specificity for a cell surface antigen, since such reagents are less tolerogenic than those that either bind to soluble antigen or have no specific target antigen in the treated recipient (as is the case with our mice given polyclonal hIgG) (Benjamin et al., 1986) .
The route of administration is also thought to influence the ability to induce suppression of an immune response. Successful tolerance has been achieved with both intravenious (i.v.) and intraperitoneal (i.p.) routes (Golub & Weigle, 1969; Pepys & Taussig, 1974; Lukic et al., 1975b) . We selected i.p. administration for our studies since this is the regional administration route used to optimise the localisation of therapeutic antibodies in our patients with ovarian cancer (Epenetos et al., 1987) . It is possible that an i.v. route might be more effective in generating immune unresponsiveness in these patients.
Our studies indicate that deaggregation alone is not sufficient to abrogate the human anti-mouse Ig response in patients with cancer undergoing monoclonal antibody therapy. The concommitant use of deaggregated immunoglobulin and cyclosporin A immunosuppression might be expected to have an additive effect in reducing the immune response, although the bone marrow toxicity and generalised immunosuppression resulting from cyclosporin A therapy make this approach less attractive. Our goal must therefore still remain the induction of tolerance that is antigen-specific, leaving the rest of the immune system intact.
